Skip to main content

Angeles Alvarez Secord, MD

Angeles Secord, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Education and Training

  • Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
  • M.D., University of Washington, 1994


  • Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011


Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment. 



Berchuck, A, Secord, AA, Moss, HA, and Havrilesky, LJ. "Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35, no. 36 (December 2017): 3999-4002.

Full Text

Tanner, E, Puechl, A, Levinson, K, Havrilesky, LJ, Sinno, A, Secord, AA, Fader, AN, and Lee, PS. "Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer." Gynecologic Oncology 147, no. 3 (December 2017): 535-540.

Full Text

Oliver, KE, Brady, WE, Birrer, M, Gershenson, DM, Fleming, G, Copeland, LJ, Tewari, K, Argenta, PA, Mannel, RS, Secord, AA, Stephan, J-M, Mutch, DG, Stehman, FB, Muggia, FM, Rose, PG, Armstrong, DK, Bookman, MA, Burger, RA, and Farley, JH. "An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience." Gynecologic Oncology 147, no. 2 (November 2017): 243-249.

Full Text

Santin, AD, Fader, A, Roque, DM, Eric, S, Buza, N, Pei, H, Abdelghany, O, Chambers, SK, Secord, AA, Havrilesky, L, O'Malley, DM, Backes, F, Nevadunsky, N, Edraki, B, Pikaart, D, Lowery, W, ElSahwi, K, Celano, P, Bellone, S, Azodi, M, Litkouhi, B, Elena, R, Silasi, DA, and Schwartz, P. "Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002).": LIPPINCOTT WILLIAMS & WILKINS, November 1, 2017.


Phippen, NT, Secord, AA, Wolf, S, Samsa, G, Davidson, B, Abernethy, AP, Cella, D, Havrilesky, LJ, Burger, RA, Monk, BJ, and Leath, CA. "Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study." Gynecologic Oncology 147, no. 1 (October 2017): 98-103.

Full Text

von Gruenigen, VE, Huang, HQ, Beumer, JH, Lankes, HA, Tew, W, Herzog, T, Hurria, A, Mannel, RS, Rizack, T, Landrum, LM, Rose, PG, Salani, R, Bradley, WH, Rutherford, TJ, Higgins, RV, Secord, AA, and Fleming, G. "Chemotherapy Completion in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer—An NRG Oncology/Gynecologic Oncology Group Study." Obstetrical & Gynecological Survey 72, no. 8 (August 2017): 481-482.

Full Text

Duska, LR, Brown, J, Danijelajelovac, , Moore, KN, McGuire, WP, Darus, C, Barroilhet, LM, and Secord, AA. "A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemictabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 2, 2017 - June 6, 2017.: AMER SOC CLINICAL ONCOLOGY, May 20, 2017.

Full Text

Gaillard, S, Dumbauld, C, Bilewski, A, Ehrisman, JA, Secord, AA, Havrilesky, LJ, Berchuck, A, Weinhold, K, Chan, C, and Yi, J. "Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8(+) T cells in ovarian cancer." May 20, 2017.

Full Text

Foote, J, Havrilesky, LJ, Jewell, EL, Gamble, C, Ehrisman, J, Broadwater, G, Coleman, RL, Cohn, DE, and Secord, AA. "Management of platinum-sensitive recurrent ovarian cancer (PSROC) in the era of biologics: Can ASCO's net health benefits (NHB) inform our decisions?." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 2, 2017 - June 6, 2017.: AMER SOC CLINICAL ONCOLOGY, May 20, 2017.

Full Text

Winder, AD, Maniar, KP, Wei, J-J, Liu, D, Scholtens, DM, Lurain, JR, Schink, JC, Buttin, BM, Filiaci, VL, Lankes, HA, Ramirez, NC, Park, K, Singh, M, Lieberman, RW, Mannel, RS, Powell, MA, Backes, FJ, Mathews, CA, Pearl, ML, Secord, AA, Peace, DJ, Mutch, DG, Creasman, WT, and Kim, JJ. "Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study." Cancer 123, no. 7 (April 2017): 1144-1155.

Full Text